【泰诺麦博：芮特韦拜单抗注射液获国家药监局批准上市】泰诺麦博公告称，公司自主研发的1类儿童专用创新药芮特韦拜单抗注射液通过优先审评审批程序获国家药品监督管理局批准上市，获批适应症为即将进入或出生在第一个呼吸道合胞病毒流行季的新生儿和婴儿预防RSV所致的下呼吸道感染。该产品为全球首款一针给药拥有长达九个月临床保护数据的RSV单抗，本次获批标志着公司第二款自主研发的全人源单克隆抗体创新药上市，不会对公司当前财务状况和经营成果产生重大影响，对未来业绩提升有一定积极作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.